cancel

Shares of the company were down more than 3%, though its studies are ongoing. An analyst wrote that the lack of revealed severe-disease suggested that any benefits observed were inconclusive. Compassionate use data last week were not definitive, but suggested potential benefit.

LEAVE A REPLY

Please enter your comment!
Please enter your name here